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19 Abstract
20 There is a complex interplay between mobility and cognition in older adults. We have 
21 previously shown that a high DHA multi-nutrient supplement improves habitual walking 
22 speed, verbal memory, and psychomotor response latency in older women. Exercise also 
23 improves mobility and cognition in older adults, and omega-3 fatty acids and exercise share a 
24 range of overlapping biological effects. This study examined for the first time the effects of 
25 the high DHA multi-nutrient supplement and aerobic exercise on mobility and cognition in 
26 older women. Women (mean age 67 y, SD 8) were assigned to the following groups: multi-
27 nutrient (1 g DHA, 160 mg EPA, 240 mg Ginkgo biloba, 60 mg phosphatidylserine, 20 mg d-
28  tocopherol, 1 mg folic acid, and 20 µg vitamin B12 per day, N=13), multi-nutrient and 
29 exercise (spin class twice per week, N=14), exercise and placebo (N=12), or placebo (N=12). 
30 The multi-nutrient was given for 24 weeks, and exercise for 12 weeks. Trial registration: 
31 NCT03228550. No treatment effects were observed for the primary outcome, habitual 
32 walking speed. Improvements in verbal memory and executive function were seen for all 
33 treatments groups versus placebo (all, p<0.05). Significant improvements in self-reported 
34 emotional wellbeing were seen with multi-nutrient and exercise groups versus placebo 
35 (p=0.03). The results suggest that the high DHA multi-nutrient supplement produces similar 
36 improvements in cognitive function to aerobic exercise, offering the intriguing prospect that 
37 supplementation may be able to mitigate some of the effects of low physical activity on 
38 cognitive function in the elderly. 
39
40
41
42
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43 Introduction 
44 Ageing is associated with a progressive decline in both cognitive and physical function, 
45 which can lead to a number of age-related health conditions including frailty and dementia (1). 
46 Walking is a complex task with a significant cognitive aspect, and changes in several gait 
47 parameters including speed often coexist with or precede the onset of cognitive decline in 
48 older adults (2). Gait speed is a clinically relevant marker in older adults, due to strong 
49 associations with physical functioning and disability (3). Previous work in our laboratory 
50 suggests a high docosahexaenoic acid (DHA) multi-nutrient supplement providing the 
51 omega-3 polyunsaturated fatty acids (PUFAs), DHA and eicosapentaenoic acid (EPA), and 
52 supporting nutrients phosphatidylserine (PS), d- tocopherol, folic acid, vitamin B12, and 
53 Ginkgo biloba, improves cognition and mobility in older females (4). 
54
55 Providing omega-3 PUFAs in combination with other compounds indicated to support brain 
56 function may provide greater efficacy than if supplemented in isolation, although results are 
57 so far mixed. For example, the same multi-nutrient supplement as used in our previous and 
58 present studies did not improve cerebral hemodynamic or cognitive function in healthy older 
59 adults (5); however, the authors acknowledge that the cognitive tests were selected on the 
60 basis that they are able to activate the prefrontal cortex, and may not be sensitive to the 
61 components in the supplement. Similarly, an omega-3 PUFA multi-nutrient supplement 
62 showed no significant effects on a battery of cognitive tests of participants with prodromal 
63 Alzheimer’s disease, although improvements were seen in secondary outcomes of cognitive 
64 function and hippocampal atrophy (6). 
65
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66 Aerobic exercise has consistently been shown to improve both mobility and cognition in 
67 older adults (7). Omega-3 PUFAs and exercise share a range of overlapping biological effects, 
68 including enhancing neurogenesis, neural plasticity, and reducing inflammation (8, 9). Indeed, 
69 preliminary evidence suggests combining omega-3 PUFAs with exercise may provide 
70 additional benefit when compared to either approach alone. For example, omega-3 PUFA 
71 supplementation combined with twice weekly stationary cycle training and cognitive 
72 stimulation led to an enhanced reduction of brain atrophy in grey matter regions compared to 
73 supplementation (10). Similarly, combining omega-3 PUFA supplementation with resistance 
74 training in older females provided an additional benefit to muscle strength compared with the 
75 exercise alone (11). In addition, an omega-3 PUFA multi-nutrient supplement combined with 
76 exercise was recently shown to improve verbal recall and executive function in older men, 
77 more than supplementation alone (12). The mechanisms underpinning these interactions are 
78 currently unclear, as the studies were not been designed to elucidate these effects. However, 
79 decreasing  Hcy levels may be a potential factor, as omega-3 PUFAs regulate the expression 
80 of genes encoding enzymes involved in Hcy metabolism (13) and exercise decreases Hcy 
81 levels (14).
82
83 The aim of this study is to further our initial observations and examine for the first time the 
84 effects of the multi-nutrient supplement and aerobic exercise on mobility and cognition in 
85 older women. The study was restricted to female participants to enable comparison with our 
86 previous work (4), and it has been suggested that the additive effects of combining exercise 
87 and omega-3 PUFA supplementation may be limited to women only (11). Women have also 
88 been shown to have a greater compliance to exercise interventions (15). Habitual gait speed 
89 was the primary outcome, with secondary outcomes related to mobility, cognition, and 
90 quality of life (16).  
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91 Methods 
92 The study is a randomised semi-blinded, placebo controlled trial in women aged 60 years and 
93 above with a factorial design. Detailed information of the study procedure has been 
94 previously published (17), in line with guidelines of the Template for Intervention Description 
95 and Replication (18). This study was conducted according to the guidelines laid down in the 
96 Declaration of Helsinki and all procedures involving human subjects/patients were approved 
97 by the Bournemouth University Science Technology and Health research ethics panel (Ethics 
98 ID 10788). Prior to data collection participants provided written informed consent. The trial 
99 was listed on www.clinicaltrials.gov (NCT03228550), and follows the Consolidated 
100 Standards of Reporting Trials (CONSORT) statement on randomised trials (19). All data was 
101 collected and analysed at Bournemouth University, U.K.
102
103 Participants 
104 Females aged 60 years and above were recruited according to the following inclusion criteria: 
105 (1) able to walk at least 50 m unaided, (2) classified as non-frail or pre-frail (20), and (3) 
106 community dwelling. Exclusion criteria were: (1) vestibular impairments, (2) diagnosed 
107 neurological disorder, (3) cognitive impairment (Mini Mental Status Examination score <24), 
108 (4) lower limb surgery, (5) seafood allergy, (6) regular consumption of multivitamin or fish 
109 oil supplements within six months prior to baseline measurements, and (6) previously 
110 received advice from a health care professional not to undertake strenuous exercise. A 
111 stratified block randomisation design was followed based on frailty classification of non-frail 
112 or pre-frail, followed by permuted block randomisation. Participant demographics can be 
113 found in Table 1. For further information please refer to the published protocol (17). 
114
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115 Interventions
116 Participants were allocated to one of four groups: multi-nutrient supplement and exercise 
117 (MS+EX), placebo supplement and exercise (P+EX), multi-nutrient supplement only (MS), 
118 or placebo supplement only (P).
119
120 Dietary supplement 
121 Participants received four capsules per day of their respective dietary supplement for 24 
122 weeks. The daily dose from the active capsules contained 1000 mg DHA, 160 mg EPA, 20 
123 µg vitamin B12, 1 mg folic acid, 124 mg PS, 240 mg Ginkgo biloba standardized leaf extract, 
124 and 20 mg vitamin E. The placebo capsules contained an isocaloric oil blend typical of the 
125 U.K. diet including a small amount of fish oil. A small amount of fish oil was added to the 
126 placebo capsules to aid with participant blinding, which provided a daily dose of 21.6 mg 
127 EPA and 14.4 mg DHA, an amount unlikely to produce any therapeutic benefit 
128 (Supplementary Table 1). Participants were told to take their capsules with the largest meal of 
129 the day. The capsules were coded by the Principal Investigator (PI), who had no involvement 
130 in the data collection, and all subsequent operational oversight and interpretation of the data 
131 was undertaken with the PI blinded to specific participant codes. Compliance to the dietary 
132 supplement was measured by changes in whole-blood DHA levels compared to baseline, 
133 counting returned pills at 12 and 24 weeks, and exit questionnaire. Adverse events were 
134 monitored by subject self-reporting and exit questionnaire.
135
136 Exercise 
137 The exercise intervention consisted of two group sessions per week on a Spinner Fit 
138 stationary bike. Classes lasted 30 min for the first six weeks and increased to 45 min for the 
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139 second six weeks, with five min warm up and cool down at 7-8 on the Borg scale of rate of 
140 perceived exertion. During the main body of the sessions participants maintained an intensity 
141 of 12-14 on the Borg scale. Compliance to the exercise intervention was monitored by 
142 recording attendances by each participant and calculated as the percentage of classes 
143 attended.
144 Outcome measures  
145 The outcome measures were based on changes in mobility, cognitive function and health 
146 related quality of life, with the primary outcome measure change in habitual walking speed. 
147 Information on the age, Body Mass Index (BMI), verbal intelligence, and medication use 
148 were collected from each participant. Information on medications was self-reported, with 
149 both type and number of medications recorded. The National Adult Reading Test 
150 (NART) was used to assess verbal intelligence. All measurements were performed at baseline 
151 and end of the study. 
152
153 Mobility
154 Participants were assessed under three gait conditions: habitual walking, fast walking, and 
155 dual task (DT) walking. During the DT participants were required to count backwards in 
156 integers of three from a randomly generated three digit number, and were not instructed to 
157 prioritise either walking or counting backwards during the task. Gait speed was measured 
158 using Opal inertial sensors and analysed using Mobility Lab™ software version 3.1 (APDM 
159 Inc, http://apdm.com). Sensors were placed over the shoes. Each tested condition was 
160 repeated five times and the mean value for each trial used for habitual and DT gait with the 
161 maximum gait speed value being used for fast walking. The five times sit to stand (5TSTS) 
162 test was used to assess dynamic balance and functional mobility. 
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163
164 Cognition
165 A Stroop test was used to assess interference control using Open Sesame version 3.1.1. 
166 software (21). Participants were presented names of one of four colours: blue, red, green, and 
167 white, in four different font colours varying between these colours. Participants were required 
168 to identify the colour of the text. Interference control was defined as the difference between 
169 the mean time taken to respond to the congruent and non-congruent trials. Spatial memory 
170 was also assessed using Open Sesame software, based upon Nagamatsu and colleagues (22). 
171 Each trial comprised presentation of three dots at randomly allocated locations for 500 ms, 
172 followed by a fixation cross for three seconds. The test comprised presentation of a single red 
173 dot on the screen, either in the same location (match) or a different (non-match) location, and 
174 participants had to identify if the test dot was match or non-match. The Rey’s Auditory 
175 Verbal Learning Test (RAVLT) was used to assess verbal memory, where participants were 
176 required to recall a list of 15 pre-set words (23). The trail making task was used to assess 
177 executive function (24), where participants drew lines between targets on a piece of paper, as 
178 rapidly as possible, under four different conditions: (1) numbers condition (one to 49), (2) 
179 letters condition, (A to Z), (3) alternated numbers (one to 25) and letters (A to X), and (4) 
180 alternated letters (A to Y) and numbers (one to 24). Scores were recorded as the total number 
181 of correct connections.
182
183 Health related quality of life
184 The short form 36 questionnaire (SF-36) was used to asses health related quality of life (25). 
185
186 Biochemical measures
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187 Biochemical measures were conducted to assess compliance to the supplementation and to 
188 better understand how changes may contribute towards any therapeutic effects on the 
189 measured outcomes.  Finger pin-prick blood samples were collected and total fatty acid 
190 content analysed, as described previously (26). Individual fatty acids were quantified using a 
191 gas chromatograph with flame ionisation detector (Agilent Technologies, U.S.A), and 
192 expressed as % of total fatty acids. A non-fasted venous blood sample was drawn to assess 
193 serum Hcy. Each sample was allowed to clot and immediately centrifuged at 2000 x g for 10 
194 min at 4⁰C and serum extracted. Samples were stored at -80C and analysed within three 
195 months. Hcy levels were measured by competitive enzyme-linked immunosorbent assay 
196 (ELISA) (Cell Biolabs Inc.) according to manufacturer’s instructions.
197
198 Diet and lifestyle 
199 Participants’ diet and lifestyle habits were monitored. Three day food diaries were used and 
200 results analysed using Nutritics dietary analysis software (www.nutritics.com). A validated 
201 food frequency questionnaire (FFQ) was used to quantify omega-3 PUFA intake (27). The 
202 community health activities program for seniors (CHAMPS) questionnaire was used to assess 
203 physical activity levels. These measures were taken  so that baseline diet and physical activity 
204 habits could be included as covariates and  to monitor whether there were any significant 
205 changes in diet and lifestyle during the course of the intervention period.
206
207 Statistical analysis 
208 Statistical analyses were performed using IBM SPSS statistics version 21 (Chicago, USA). 
209 Sample size was determined based on the primary outcome of habitual walking speed. Using 
210 an effect size based on previously published values, minimally significant changes in gait 
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211 speed were 0.03 m/s and 0.05 m/s with substantial changes at 0.08 m/s (28). The sample size 
212 calculation was based on a difference of 0.08 m/sec with the level of variability set at 0.1 
213 based on our previous work (4) with a minimum sample size of 13 participants per group 
214 required to detect an effect size d of 0.5. In our original protocol a large effect size was 
215 suggested; however, this was subsequently changed to a medium effect size based on our 
216 previous pilot study (4, 17). Data were tested for normal distribution using Shapiro-Wilk test 
217 and Q-Q-plots and Levenes test of equality of error variances to check for assumptions of 
218 homogeneity. Correlations between mobility, cognitive function, and health related quality of 
219 life, exercise, circulating omega-3 PUFAs and Hcy were examined using partial correlations, 
220 controlling for age, BMI and dietary protein. For any variables that did not meet the 
221 assumptions of normality for partial correlations a syntax was used to produce a non-
222 parametric partial correlation. This method consisted of using the NONPAR CORR and 
223 /MATRIX OUT commands to produce a Spearman Rho matrix, which could then be read by 
224 the /MATRIX IN and PARTIAL CORR command whilst factoring in the appropriate 
225 covariates. For all correlation analysis a sample size of 46 was required to achieve a power of 
226 0.80 for a correlation coefficient of 0.40 and an α of 0.05 (29). Evidence suggests a non-linear 
227 relationship between Hcy and health of older adults (30), therefore non-parametric correlation 
228 analysis was performed. NART score was included as a covariate in preliminary analysis, but 
229 was excluded in final models. 
230 Baseline and 24 week results from the diet and physical activity assessments were compared 
231 within groups, using paired T-tests. A general linear model was used to compare the active 
232 intervention groups versus the placebo over time (from pre- to post-measurement) on changes 
233 on the dependent variables on an intention to treat basis. Effect size calculation (η² (Eta 
234 squared)) was performed. Demographic and health information, such as age, and BMI were 
235 included as covariates in the analysis if they were significantly correlated with the dependent 
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236 variable. The Benjamini-Hochberg procedure was used to decrease the false discovery rate 
237 and probability of type I errors, with a Q value of <0.25 accepted as significant, and all P 
238 values are expressed as raw values (31). Linear regression we used to identify whether a 
239 difference in whole-blood DHA was associated with a change in outcome score. All results 
240 are expressed as means (SD). Pre-trial registration plans dictated that a 2 x 2 ANOVA would 
241 be conducted to examine treatment effects, however due to the potential interaction between 
242 the supplementation and exercise independence of these variables could not be guaranteed, 
243 thus examining treatment effects based on the assigned groups was determined to be a more 
244 robust method. Correlation analysis was used to identify whether a difference in whole-blood 
245 DHA was associated with a change in outcome score. All results are expressed as means 
246 (SD).
247
248 Results 
249 Participant flow is shown in Fig 1. The study had three separate intakes of participants, 
250 starting in March 2017, May 2017, and February 2018, with data collection taking place 
251 between March 2017 and January 2019. In total 60 participants were allocated to intervention 
252 groups and 51 completed the study. Analyses were conducted on all who completed the study 
253 with no exclusions irrespective of compliance or protocol violations. Participants who 
254 withdrew during the study were invited to attend follow up assessment; however, the 
255 invitations were declined. Role limitations due to physical health problems, role limitations 
256 due to emotional health problems, and social functioning from the SF-36 questionnaire 
257 showed clear signs of ceiling effects, therefore these were omitted from analysis. Hcy data 
258 was only available for 48 baseline values. Upon inspection four results of the baseline whole-
259 blood DHA levels were identified as unreliable and were subsequently excluded from the 
260 analysis. 
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261
262 The group baseline characteristics are shown in Table 1. There were no reported adverse 
263 effects in any group over the study. The multi-nutrient supplementation led to significant 
264 increases in DHA and EPA compared to baseline levels in the MS (28% and 190%, 
265 respectively) and MS+EX (43% and 140%, respectively) groups, and significant decreases in 
266 the omega-6 PUFA, arachidonic acid levels of -28% and -26%, respectively, all p < 0.05, 
267 Table 2. Compliance to the supplementation measured via changes in DHA and was 91% for 
268 MS+EX, and 80% for MS, 100% for P+EX and 100% for P, which was corroborated by 
269 capsule counting. Compliance to the exercise intervention was 55% for MS+EX and 56% for 
270 P+EX, which is consistent with other exercise intervention trials in a similar demographic (22). 
271 There were no significant changes in reported calorie, macronutrient or omega-3 PUFA 
272 intake between baseline and follow up, Table 2. Participants maintained their current use of 
273 medications and there were no reported changes health status throughout the duration of the 
274 study with the exception of two participants in the MS+EX who discontinued their use of 
275 analgesic and anti-inflammatory medications. 
276
277 Primary outcome measure
278 There was a non-significant decrease of 0.8% in the mean habitual walking speed by the P 
279 group over the study; whereas, the other groups increased their mean walking speed by 0.05 
280 m/s (0.07 m/s) (4.0%) for the MS group, 0.03 m/s (0.09 m/s) (2.5%) for the P+EX group, and 
281 0.01 m/s (0.12 m/s) (0.8%) for the MS+EX group. However, these changes were not 
282 statistically significant for supplementation (p = 0.25), exercise (p = 0.50) or for the 
283 combined intervention (p = 0.79), Fig 2.
284
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285 Secondary outcome measures
286 The results for the effects of the interventions on mobility, cognition, and health related 
287 quality of life are summarised in Table 3. There was a significant effect on verbal memory 
288 compared with the P group, by the MS [F(1,46) = 7.59, p = 0.008, partial η2 0.144)], P+EX 
289 [F(1,46) = 7.70, p = 0.008, partial η2 0.144] and MS+EX interventions [F(1,46) = 15.82, p < 
290 0.001, partial η2 0.256], all with large effect sizes, Fig 3. Significant effects versus placebo 
291 were also observed for executive function for the MS [F(1,47) = 8.02, p = 0.007, partial η2 
292 0.146)], P+EX  [F(1,47) = 8.37, p = 0.006, partial η2 0.151)], and MS+EX groups [F(1,47) = 
293 8.60, p = 0.005, partial η2 0.155)] all with large effect sizes, Fig 4. The MS+EX group also 
294 reported significant improvements in emotional wellbeing, compared to the P group [F(1,47) 
295 = 8.07, p = 0.03, partial η2 0.146], with a large effect size. No significant treatment effects 
296 were observed for the other outcomes.
297
298 Correlations of outcomes with DHA status and Serum Hcy
299 Significant baseline relationships between DHA and DT gait speed r(53) = 0.32, p = 0.018, 
300 bodily pain r(51) = 0.35, p = 0.013 and emotional wellbeing r(51) = 0.30, p = 0.032 from the 
301 SF-36 questionnaire were identified. These relationships were moderate to weak in strength. 
302 There were no significant associations between DHA and any cognitive outcomes. Following 
303 the interventions there was a direct relationship between changes in verbal memory and DHA 
304 levels, r(18) = 0.66, p = 0.001, Fig 5, however no relationship was detected for changes in 
305 executive function. At baseline there were no significant associations between serum Hcy and 
306 any of the outcome measures (Supplementary Table 2).
307
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308 Discussion 
309 The MOBILE study explores for the first time the effects of a high DHA multi-nutrient 
310 supplement and aerobic exercise on mobility and cognition in older women. Although the 
311 supplementation led to significant increases in DHA levels, there were no significant 
312 improvements in the primary outcome measure of habitual walking speed. However, 
313 significant improvements in verbal memory and executive function were seen following the 
314 interventions, with the improvements in verbal memory in direct relation to increases in 
315 whole-blood DHA levels. Furthermore, lower circulating DHA was associated with poorer 
316 DT performance, and measures of pain and emotional wellbeing at baseline. 
317
318 Significant improvements in habitual walking speed were previously shown by us following 
319 treatment with the same multi-nutrient supplement, reflecting clinically relevant 
320 improvements within a similar sample size (4). These improvements were driven by both 
321 improvements in the treatment group and decreases in the placebo group. However, in the 
322 present study although there were increases following the multi-nutrient supplementation of a 
323 similar magnitude to our previous study, the decline in the placebo group was much less than 
324 predicted, with a mean decline of 0.8%, as opposed to 2% in our previous study (32), which 
325 may reflect a high functioning nature of the participants. Indeed, the lack of improvement 
326 following the exercise intervention supports this hypothesis, as aerobic exercise has 
327 consistently been shown to improve walking speed (33, 34). Interestingly the effect size for the 
328 combined supplementation and exercise group was modest in comparison to each 
329 intervention on their own however this may be partly explained by the aforementioned 
330 participants who discontinued daily use of analgesic and anti-inflammatory for joint pain who 
331 both observed small declines in gait speed of 0.01 m/s.
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332 The individual and combined interventions led to improvements in verbal memory, with the 
333 total recall across the trials representing eight to twelve more words remembered than the 
334 placebo group. These findings corroborate previous observations showing positive effects on 
335 verbal memory following treatment with the same multi-nutrient supplement (4). Similarly, 
336 the improvements following exercise are consistent with previous research (7). The individual 
337 and combined interventions also resulted in significantly improved executive function. The 
338 observation of exercise improving this cognitive domain is consistent with previous 
339 experimental work (7). There is currently no clear consensus in the literature as to whether the 
340 factors in the multi-nutrient supplement improve executive function in older adults. For 
341 example, 900 mg DHA for 24 weeks had no effect on executive function (35), whereas 1320 
342 mg EPA and 880 mg DHA for 26 weeks produced significant improvements (36). Similarly, 
343 although B vitamins (37) and Ginkgo biloba (38) do not appear to improve executive function, 
344 preliminary evidence suggests PS has some beneficial effects (39). A recent study suggested an 
345 omega-3 PUFA multi-nutrient supplement combined with exercise improves executive 
346 function in older men (12); however, as there was no exercise only control group the 
347 contribution of omega-3 PUFA multi-nutrient supplement to these effects cannot be 
348 identified. Indeed our analysis found no significant relationship between changes in blood 
349 level of DHA and the executive function suggesting that other factors may have contributed 
350 towards the change in this outcome.
351 Due to the small sample size analysis to detect superiority of the active interventions over one 
352 another was not possible. It may be hypothesised that the effects of the multi-nutrient 
353 supplement and exercise operate via overlapping biological mechanisms. This includes 
354 decreasing inflammation, for example, interleukin 6 (IL-6) levels are linked to declines in 
355 verbal memory (40), and both omega-3 PUFAs and aerobic exercise have both been shown to 
356 decrease IL-6 levels (41). Alternatively, exercise and factors in the multi-nutrient supplement, 
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357 such as DHA and Ginkgo biloba increase brain-derived neurotrophic factor (BDNF) levels, 
358 which may contribute to enhancing synaptic plasticity and cognitive function (42-44). However, 
359 further work is needed to explore these potential mechanisms, if they mediate any of the 
360 observed effects and if indeed the combination of the two interventions can provide an 
361 additional benefit to the older adult.
362 Due to the range of compounds in the multi-nutrient supplementation it is not possible to 
363 ascribe the effects to any single factor, and the present results further support the use of a 
364 combination of dietary factors in aging (4, 45). Unfortunately, due to methodological issues we 
365 were unable to monitor changes in serum Hcy levels over the study and so cannot identify the 
366 potential role of folic acid and vitamin B12 in the treatment effects. However, a major 
367 unifying factor in the multi-nutrient intervention is DHA, and the supplementation increased 
368 circulating DHA and EPA levels. To identify the potential contribution of DHA to the 
369 treatment effects correlations between changes in DHA and changes in outcome measures 
370 were performed. The increases in DHA levels over the study were in direct relation with 
371 improvements in verbal memory, suggesting increasing DHA was an important contributor to 
372 the treatment effects on this outcome. At baseline, significant relationships were seen with 
373 DHA and DT gait speed, although no other measures of mobility or cognition. Previous 
374 observations suggest circulating DHA levels correlate with gait and mobility outcomes (4, 46) , 
375 although erythrocyte DHA and EPA was not shown to be associated with a slower decline in 
376 gait speed over three years in a fully adjusted model (47). The results from the present study do 
377 provide some further support for DHA status as a potential blood biomarker for monitoring 
378 physical performance in aging, although further work is needed to establish this link more 
379 clearly. 
380 The strengths of this study are that it was randomised, placebo controlled semi-blinded 
381 design, with high retention rate, thereby increasing the reliability of the data. The study used 
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382 a range of detailed and sensitive mobility and cognitive tests to assess treatment effects. It is 
383 important in this type of study to monitor participant’s dietary intake and physical activity; 
384 these were assessed by diet diary and FFQ, and CHAMPS questionnaire, respectively. This 
385 meant it could be confirmed that the participants diet and physical activity outside of the 
386 interventions remained consistent. The only notable, although not statistically significant, 
387 change in diet was a decrease in fat intake across all four groups; however we have no reason 
388 to believe this decrease across the groups would have influenced the results of the analysis. 
389 Furthermore, the trial design was reviewed and made publicly available on a clinical trials 
390 registry and was subject to peer review during the protocol publication process. Additionally, 
391 blood fatty acid levels were taken at the start and end of the study, to monitor absorption and 
392 incorporation of the omega-3 PUFAs. Limitations were the low recruitment, and high 
393 functional ability of the participants. A further limitation was that ApoE genotype was not 
394 assessed, as this may affect participant’s response to the supplementation (48), and is 
395 associated with gait speed decline in aging (49). 
396
397 Conclusions
398 Overall, these results suggest that the multi-nutrient supplement produces similar 
399 improvements in verbal memory and executive function to aerobic exercise, offering the 
400 intriguing prospect that supplementation may be able to mitigate some of the effects of low 
401 physical activity on cognitive function in the elderly. These improvements are clinically 
402 relevant and were identified in able female adults. Treatment effects were not identified in the 
403 primary outcome, nonetheless the improvements in verbal memory and executive function 
404 does provide some promising insight into the benefits of dietary supplementation and 
405 exercise for the promotion of healthy ageing. The study identified for the first time 
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406 relationships between DHA and DT ability. Further work should seek to explore the effects 
407 of the supplement on participants who may be most likely to respond, i.e. those with low 
408 DHA and high Hcy levels, and also explore supplementation for a longer period, or in a more 
409 frail population.
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562
563
564 Figure 1 Participant flow through study 
565
566 Figure 2 Effects of multi-nutrient supplement and exercise on the primary outcome of 
567 habitual gait speed. There were no significant effects for any intervention on changes in gait 
568 speed.
569
570 Figure 3 Effects of multi-nutrient supplement and exercise by general linear model on Rey’s 
571 auditory verbal learning test. Significant effects for multi-nutrient supplement (p = 0.008) 
572 placebo supplement and exercise (p = 0.008) and combination of multinutrient and exercise 
573 (p < 0.001). See text for further detail.
574 * Indicates a significant effect of the intervention on changes in verbal memory versus 
575 placebo. 
576
577 Figure 4 Effects of multi-nutrient supplement and exercise by general linear model on 
578 executive function. Significant effects for multi-nutrient supplement (p = 0.007) placebo 
579 supplement and exercise (p = 0.006) and combination of multinutrient and exercise (p < 
580 0.005). See text for further detail.
581 * Indicates a significant effect of the intervention on changes in executive function versus 
582 placebo. 
583
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584 Figure 5 Scatter plot for changes in DHA and change in verbal memory for MS and P groups, 
585 r(18) = 0.66, p = 0.001.
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Table 1 Participant characteristics at baseline.  
*Indicates value is the median (IQR), otherwise means (SD) presented.
Parameter PL
(N = 12)
PL + EX
(N = 12)
MS
(N = 13)
MS + EX
(N = 14)
Age (years) 67 (4) 67 (4) 69 (4) 68 (5)
Height (m) 1.63 (0.1) 1.64 (0.1) 1.62 (0.1) 1.61 (0.1)
Weight (kg) 69.5 (14.9)* 77.1 (33)* 75.6 (17.4)* 68.6 (11.1)*
BMI (kg/m2) 26.8 (5.2)* 27.8 (12.0)* 27.4 (5.3)* 28.6 (5.9)*
Comorbidities Hypertension (2)
Hypercholesterolemia (1)
Osteoarthritis  (2)
Hypertension (3)
Osteoarthritis (1)
Hypertension (2)
Hypercholesterolemia (1)
Osteoporosis (1)
Hypertension (3)
Hypercholesterolemia (2)
Diabetes (1)
Osteoarthritis (2)
NART Score 36 (8) 36 (5) 37 (5) 36 (7)
MMSE score 30 (1)* 30 (0)* 30 (1)* 30 (2)*
Hand Grip 
Strength (kg)
20.5 (3.4) 21.0 (5.9) 19.3 (5.4) 19.0 (4.0)
PASE Score 114 (97)* 113 (30)* 111 (73)* 100 (55)*
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Abbreviations: Mini Mental Sate Exam, MMSE; National Adult Reading Test, NART; Physical Activity Scale in the Elderly, PASE
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* Indicates a significant change versus baseline, assessed using paired T-test or Wilcoxon signed-rank test where appropriate 
a N = 10 and b N = 10 for whole-blood fatty acid value
Table 2: Participant compliance
   Parameter PL
(N = 12)a
PL+EX 
(N = 12)
MS 
(N = 13)b
MS+EX 
(N = 14)
Baseline 24 weeks Baseline 24 weeks Baseline 24 weeks Baseline 24 weeks
Fatty acid levels (% total fatty acids)
ARA 6.6 (1.2) 6.3 (1.5) 6.7 (2.0) 6.9 (1.1) 7.1 (3.4) 5.1 (1.2)* 6.9 (2.0) 5.1 (1.4)*
EPA 0.4 (0.2) 0.4 (0.2) 0.4 (0.2) 0.4 (0.3) 0.3 (0.1) 0.9 (0.2)* 0.4 (0.2) 0.8 (0.4)*
DHA 1.7 (0.4) 1.6 (0.4) 1.7 (0.6) 1.5 (0.4) 1.8 (0.6) 2.3 (0.5)* 1.5 (0.4) 2.1 (0.6)*
Dietary intake per day
Kcal 1869 (440) 1772 (518) 1530 (386) 1507 (310) 1642 (464) 1489 (439) 1738 (293 1565 (339)
Carbohydrate (g) 190 (41) 180 (51) 156 (45) 154 (43) 175 (49) 168 (51) 175 (33) 164 (39)
Protein
(g/kg bodyweight)
1.12 (0.38) 1.11 (0.34) 0.91 (0.40) 0.91 (0.36) 1.00 (0.26) 0.93 (0.28) 1.09 (0.19)  0.96 (0.21)
Fat (g) 84 (25) 76 (31) 68 (23) 62 (10) 67 (27) 63 (25) 73 (19) 66 (23)
Physical activity 
CHAMPs (kcal) 3619 (2159) 3390 (1686) 3454 (2009) 4011(2622)* 4314 (2328) 3945(2098) 3289 (1537) 3650 (1523)*
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Table 3 Secondary outcome measures displayed as mean (SD)
 Parameter PL 
(N = 12)
PL + EX 
(N = 12)
MS 
(N = 13)
MS + EX 
(N =14)
Baseline 24 weeks Baseline 24 weeks Baseline 24 weeks Baseline 24 weeks
Mobility 
Fast Walking 
Speed (m/s)
1.8 (0.3) 1.7 (0.2) 1.6 (0.3) 1.6 (0.2) 1.6 (0.2) 1.6 (0.2) 1.7 (0.2) 1.7 (0.2)
DT Gait Speed 
(m/s)
0.9 (0.3) 1.0 (0.2) 1.1 (0.2) 1.1 (0.2) 1.0 (0.3) 1.0 (0.3) 1.2 (0.3) 1.2 (0.3)
Five Times Sit 
to Stand (s)
11.8 (2.1) 11.7 (2.3) 13.9 (3.9) 13.0 (3.0) 11.9 (2.1) 11.9 (2.2) 13.9 (3.9) 12.3 (2.6)
Cognition 
Verbal 
Memory (%)
58 (11) 54 (16) 61 (14) 67 (13) 54 (13.0) 60 (13) 58 (13) 67 (15)
Spatial 
Memory (%)
75 (7) 75 (6) 77 (5) 75 (6) 77 (7) 73 (7) 75 (7) 72 (10)
Executive 
Function 
(Correct 
Connections)
80 (18) 75 (19) 68 (21) 76 (23) 60 (15) 67 (21) 68 (18) 75 (15)
Interference 
Control (ms)
159 (90) 152 (77) 149 (96) 118 (104) 210 (106) 189 (104) 205 (198) 169 (148)
SF-36 Questionnaire 
Physical 
Function
79 (24) 78 (26) 75 (21) 79 (19) 82 (15) 83 (16) 75 (26) 77 (22)
Bodily Pain 75 (24) 73 (25) 75 (22) 80 (13) 74 (19) 77 (17) 66 (21) 66 (16)
Emotional 
Wellbeing
75 (23) 72 (24) 82 (17) 80 (14) 79 (14) 79 (13) 69 (18) 74 (17)
Energy
/ Fatigue
57 (25) 55 (25) 65 (26) 67 (24) 62 (22) 63 (19) 58 (25) 58 (24)
General 
Health 
66 (23) 70 (23) 75 (18) 76 (18) 66 (16) 66 (19) 62 (24) 62 (24)
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Supplementary Table 1 Fatty Acid Composition of Placebo Capsules.
Fatty Acid Profile % Fatty Acid Methyl Ester Milligram triglyceride  
per Capsule
14:0 Myristic 0.4 3.3
16:0 Palmitic 7.3 67.8
16:1 Hexadecenoic 0.5 4.2
16:3 Heptadecatrienoic 0.1 0.5
16:4 Hexadecatetraenoic 0.1 0.8
17:0 Heptadecanoic 0.1 0.5
18:0 Stearic 6.6 60.3
18:1 (n-9) Oleic 72.4 656.5
18:1 (n-7) CIS-vaccenic 0.8 6.8
18:2 (n-7) Linoleic 8.2 74.1
18:3 (n-3) Alpha-linoleic 0.1 1.1
18:4 (n-3) Octadecatetraenoic 0.1 1.2
20:0 Icosanoic 0.3 2.7
20:1 Icosenoic 0.3 3.0
20:4 (n-6) Arachidonic 0.0 0.4
20:5 (n-3) Icosapentaenoic 0.8 6.8
22:0 Docosanoic 0.9 7.6
22:1 (n-11) Cetoleic 0.1 0.8
22:5 (n-3) Docosapentaenoic 0.1 0.7
24:0 Tetracosanoic 0.3 2.5
22:6 (n-3) Docosahexaenoic 0.5 4.3
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Supplementary Table 2 Correlation matrix plotting serum homocysteine against 
primary and secondary outcome measures.
Outcome Measure Homocysteine Correlation 
Habitual Gait Speed (m/s) R=0.190 (p=0.197)
Fast Walking Speed (m/s) R=0.256 (p=0.079)
Dual Task Gait Speed (m/s)  R=-0.005 (p=0.975)
DTE on Gait Speed (%)  R=-0.209 (p=0.155)
Dual Task Variability (%) R=0.040 (p=0.788)
FTSTS (s) R=
Verbal Memory (%) R=-0.093 (p=0.528)
SWM (%) R=-0.194 (p=0.187)
EF (number of correct connections) R=0.218 (p=0.136)
Interference control (ms) R=-0.158 (p=0.283)
Physical Function (SF-36 score) R=0.083 (p=0.591)
Emotional Wellbeing (SF-36 score) R=-0.289 (p=0.057)
Energy/ Fatigue (SF-36 score) R=0.042 (p=0.787)
Bodily Pain (SF-36 score) R=-0.050 (p=0.749)
General Health Perceptions (SF-36 score) R=-0.138 (p=0.373)
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